My Life as a Lobbyist

Key Takeaways

• Medicare cuts reduced joint replacement payments 55% over 20 years
• Surgeons lead alternative payment models, yet face decreasing reimbursements
• Advocacy fragmented; physicians lack unified lobbying power
• CMS shifts models toward hospitals, limiting specialist control
• Proposed ISTACA bill cost-neutral, supports prior authorization reform

Summary

Orthopedic surgeons from the American Association of Hip and Knee Surgeons spent a day lobbying in Washington, D.C., highlighting steep Medicare reimbursement cuts and advocating for continued support of alternative payment models (APMs). The group met with congressional staff, testified at a subcommittee hearing, and pushed for the Improving Seniors Timely Access to Care Act (ISTACA) to reform prior authorization. Data presented showed a 55% decline in inflation‑adjusted payments for hip and knee replacements over two decades, while surgeons argue they have delivered cost‑saving value through bundled‑payment programs. The experience underscored the fragmented nature of physician advocacy and the growing disconnect between policymakers and specialists.

Pulse Analysis

The orthopedic community is confronting an unprecedented erosion of Medicare reimbursement, with inflation‑adjusted payments for total hip and knee arthroplasty falling more than half since 2000. This trend reflects broader policy choices that prioritize primary‑care prevention at the expense of high‑volume specialty procedures, even as surgeons have demonstrated superior outcomes and lower episode costs through bundled‑payment initiatives. When reimbursement drops below sustainable levels, specialists may consider exiting Medicare, a move that would strain access for an aging population and shift costs back onto the system through complications and delayed care.

Value‑based care remains a central pillar of the surgeons' argument. Orthopedic groups have been early adopters of alternative payment models, consistently delivering greater cost reductions than hospital‑led programs. Yet recent CMMI models such as TEAM and ACCESS reallocate financial control to health systems, marginalizing surgeon input. By positioning specialists as passive passengers rather than drivers of value, policymakers risk undermining the very efficiencies these models were designed to capture. Evidence shows physician‑led bundles can cut episode costs by over $800, underscoring the need for policies that preserve specialist leadership in payment design.

The lobbying effort highlighted a systemic weakness: fragmented physician advocacy against well‑funded hospital, insurer, and pharma lobbies. Meetings with congressional aides revealed limited policy expertise, while low attendance at hearings signaled a missed opportunity for meaningful dialogue. Data‑driven lobbying—presenting clear cost‑benefit analyses and patient‑outcome metrics—offers a pragmatic path forward. Aligning surgeon interests with bipartisan priorities, such as the cost‑neutral ISTACA bill, could forge the consensus needed to protect reimbursement levels, sustain access, and maintain the broader goal of affordable, high‑quality orthopedic care.